Pharminent

FDA clears Merck’s Keytruda for cancer patients with certain biomarkers

(Reuters) – The U.S. Food and Drug Administration on Tuesday approved Merck & Co’s immuno-oncology treatment, Keytruda, for cancer patients who carry a specific genetic feature.

http://www.reuters.com/article/us-merck-co-fda-idUSKBN18J2T9

Filed under: Cancer, Immunotherapy